Citations to this article

The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor.
K M Argraves, … , P C Harpel, D K Strickland
K M Argraves, … , P C Harpel, D K Strickland
Published November 1, 1997
Citation Information: J Clin Invest. 1997;100(9):2170-2181. https://doi.org/10.1172/JCI119753.
View: Text | PDF
Research Article Article has an altmetric score of 3

The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor.

Abstract

Research Article

Authors

K M Argraves, K F Kozarsky, J T Fallon, P C Harpel, D K Strickland

×

Total citations by year

Year: 2025 2024 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 Total
Citations: 3 5 1 3 6 4 7 11 4 8 3 3 3 5 2 3 1 1 1 5 4 6 1 7 5 10 7 119
Citation information

Citations to this article in year 2017 (11)

Title and authors Publication Year
Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation
S Takahashi 		Journal of Atherosclerosis and Thrombosis 2017
Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9
R Romagnuolo, CA Scipione, SM Marcovina, M Gemin, NG Seidah, MB Boffa, ML Koschinsky, MC Vinci 		PloS one 2017
PCSK9 targets important for lipid metabolism
R Schulz, KD Schlüter 		Clinical Research in Cardiology Supplements 2017
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
KL Ellis, MB Boffa, A Sahebkar, ML Koschinsky, GF Watts 		Progress in Lipid Research 2017
Lipoprotein(a) in clinical practice: New perspectives from basic and translational science
CA Scipione, ML Koschinsky, MB Boffa 		Critical Reviews in Clinical Laboratory Sciences 2017
Genetics of Dyslipidemia and Ischemic Heart Disease
K Sharma, RR Baliga 		Current Cardiology Reports 2017
Vascular lesions in patient with Takayasu arteritis and massive elevated lipoprotein (a) levels. Residual involvement or premature aterosclerosis?
JC García, SR Suárez, OM Grijalvo, SG Morillo 		Clínica e Investigación en Arteriosclerosis (English Edition) 2017
Usefulness of Lipoprotein(a) for Predicting Clinical Outcomes After Endovascular Therapy for Aortoiliac Atherosclerotic Lesions
K Hishikari, H Hikita, S Nakamura, S Nakagama, M Mizusawa, T Yamamoto, J Doi, Y Utsugi, Y Sudo, S Kimura, T Ashikaga, A Takahashi, M Isobe 		Journal of Endovascular Therapy 2017
PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease
MM Page, GF Watts 		Diabetes, obesity & metabolism 2017
Lipoprotein(a): A missing culprit in the management of athero-thrombosis?
G Ferretti, T Bacchetti, TP Johnston, M Banach, M Pirro, A Sahebkar 		Journal of Cellular Physiology 2017
Lesiones vasculares en paciente diagnosticada de arteritis de Takayasu y elevación masiva de lipoproteína(a). ¿Afectación residual o arterioesclerosis prematura?
JC García, SR Suárez, OM Grijalvo, SG Morillo 		Clínica e Investigación en Arteriosclerosis 2017

Advertisement